The person who's done this study into people with type 2 diabetes is Dr. Tamara Milder, who's an endocrinologist and a researcher at the Medicines Intelligence Research Program.

the drug class known as SGLT2 inhibitors.

We have two available.

They're empagliflozin and dipagliflozin.

So we're talking about Jardien's and for Seagull.

So these are quite common tablet medications that were designed to treat type 2 diabetes, but very importantly, they were found to have major heart and kidney benefits.

Now they are a major drug therapy for heart failure and chronic kidney disease, whether or not you have diabetes.

And the question is, were they stopped too and were they restarted?